Abdulrazaq Mohammed, Hamdan Farqad, Al-Tameemi Waseem
Department of Physiology, College of Medicine, Al-Nahrain University, Baghdad, Iraq.
Department of Medicine, College of Medicine, Al-Nahrain University, Baghdad, Iraq.
Iran J Basic Med Sci. 2015 Aug;18(8):737-44.
In this study, we aimed at evaluation of electrophysiological and histopathalogical characteristics of statin-induced muscle injury as well as clinical features of patients who develop this condition in terms of frequency and pattern of evolution.
Forty patients (age 39-74 years) including 25 subjects with type 2 diabetes mellitus, 9 with cardiovascular diseases and 6 with hyperlipidemia, who were receiving atrovastatin 40 mg/day for variable period, were studied. Thirty three healthy subjects (age 31-74 years) served as control group. Creatine phosphokinease level, thyroid function, motor unit potential parameters and muscle fiber conduction velocity of biceps brachii and tibialis anterior muscles were measured.
Creatine phosphokinase level was elevated in statin users, particularly in those with diabetes mellitus. Less than 50% of statin users experienced symptoms related to muscle injury. Muscle fiber conduction velocity of the biceps brachii muscle was significantly reduced. Statin users with diabetes mellitus showed significant changes in electrophysiological parameters as compared to those with cardiovascular diseases and hyperlipidemia. Muscle biopsies showed muscle fiber variation in size, fibrosis and mild inflammatory cell infiltration. Immunohistochemical evaluation of muscle biopsies showed positive expression of Bcl-2 and one patient showed positive P53 immunohistochemical expression with elevated level of creatine phosphokinase.
Atorvastatin increased average creatine kinase, statins produce mild muscle injury even in asymptomatic subjects. Diabetic statin users were more prone to develop muscle injury than others. Muscle fiber conduction velocity evaluation is recommended as a simple and reliable test to diagnose statin-induced myopathy instead of invasive muscle biopsy.
在本研究中,我们旨在评估他汀类药物所致肌肉损伤的电生理和组织病理学特征,以及出现这种情况的患者的临床特征,包括其发生频率和演变模式。
研究了40例患者(年龄39 - 74岁),其中包括25例2型糖尿病患者、9例心血管疾病患者和6例高脂血症患者,他们接受阿托伐他汀40 mg/天治疗的时间各不相同。33例健康受试者(年龄31 - 74岁)作为对照组。测量了肌酸磷酸激酶水平、甲状腺功能、运动单位电位参数以及肱二头肌和胫前肌的肌纤维传导速度。
他汀类药物使用者的肌酸磷酸激酶水平升高,尤其是糖尿病患者。不到50%的他汀类药物使用者出现与肌肉损伤相关的症状。肱二头肌的肌纤维传导速度显著降低。与心血管疾病和高脂血症患者相比,糖尿病他汀类药物使用者的电生理参数有显著变化。肌肉活检显示肌纤维大小变异、纤维化和轻度炎性细胞浸润。肌肉活检的免疫组织化学评估显示Bcl - 2呈阳性表达,1例患者P53免疫组织化学表达阳性且肌酸磷酸激酶水平升高。
阿托伐他汀使平均肌酸激酶升高,他汀类药物即使在无症状受试者中也会产生轻度肌肉损伤。糖尿病他汀类药物使用者比其他人更容易发生肌肉损伤。建议将肌纤维传导速度评估作为诊断他汀类药物所致肌病的一种简单可靠的检测方法,而非进行有创的肌肉活检。